Paradigm-medical
“Paradigm held a special shareholders meeting on December 18, 2009 at its new facility. The purpose of the meeting was to present the results of the shareholders proxy votes on two proposals presented and supported by the Paradigm Board of Directors. The first proposal was to change the par value from .001/share to .0001/share. Shareholders approved this proposal. The second was to increase the authorized shares from 1.4 Billion shares to 28 Billion shares. This proposal was also approved by the shareholders. The shareholders approval will allow Paradigm to move ahead with its plans to secure additional funding to allow it to take full advantage of its new growth opportunities.”
                                                                                           
Stephen L Davis
President/CEO
(801) 977-8970
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Little About Us

 

We specialize in the development and marketing of diagnostic equipment for the ophthalmic market. Our product families of topographers, autoperimeters and ultrasonic biomicroscopes combined withour unique Blood Flow Analyzer help the eye care professionals community diagnose and treat disorders of the eye such as glaucoma, cataracts and age-related macular degeneration.

 

Featured Products

P2700 A/B Scan
P2700 A/B Scan
 Call for Pricing		 P60 UBM
P60 UBM
 Call for Pricing